Browse by ▼

Amarin Corp plc (ADR)

  • Two Different Outlooks for Two Tuesday Performers

    By Brian Nichols - May 2, 2013 | Tickers: AMRN, RPTP

    It’s nothing new for biotech stocks to see significant movement in a day’s session, although sometimes these moves create a trap for the retail investors who buy at inflated prices. Hence I am looking at two stocks in particular that saw nice jumps on Tuesday but have different outlooks.

    Stock Gains with FDA Approval

    Raptor Pharmaceuticals (NASDAQ: RPTP) saw a gain of 8.70% on Tuesday after announcing more »

  • Can This New Drug Win Against Established Competitors?

    By Shas Dey - April 27, 2013 | Tickers: ABT, AMRN, GSK

    It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying about Amarin (NASDAQ: AMRN), which has a new drug out to cater to a vast number of patients in the cardiovascular realm. The phase III trial results have all been positive, yet, the presence of established competitors can leave some more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • AstraZeneca is Headed in the Right Direction

    By Mohsin Saeed - March 27, 2013 | Tickers: AMRN, AZN, SHPG

    In my last report on AstraZeneca (NYSE: AZN), I focused on the patent expiry of Seroquel IR and the resultant decline in company sales. According to recent news, the troubles of AstraZeneca are still not over and the company is cutting approximately 2,300 sales and admin jobs. This is part of a large plan put forward by the new CEO to jump start falling sales.

    Strategy shift

    The new more »

  • More Good News for Amarin

    By Mohsin Saeed - March 14, 2013 | Tickers: AMRN, GSK

    Last year, a number of drugs received FDA approval. The drug authority has rolled out one approval after another, maybe to compensate for the patent cliff most large pharmaceuticals are facing. These approvals have a significant impact on single drug companies, such as Amarin (NASDAQ: AMRN). The company's stock has traded as high as $19.50 on positive expectations from its star drug Vascepa. Small biopharmaceuticals with approved candidates more »

  • 3 Bio-Pharmaceuticals You Can't Ignore

    By Mohsin Saeed - February 26, 2013 | Tickers: AMRN, ARNA, VVUS

    The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the SPDR S&P Biotech ETF (XBI) and iShares NASDAQ Biotechnology Index (IBB), giving returns of more than 20%. The entire industry is heavily dependent for growth on the approvals of the Food and Drug Administration (FDA). According to more »

  • A Buyout In Amarin Is Imminent!

    By Terry Chrisomalis - February 22, 2013 | Tickers: AMRN, GSK, PFE

    All throughout Wall Street we keep hearing about Amarin (NASDAQ: AMRN) being bought out by some type of Big Pharma company in the future.  It's all rumors circling around, but it's one of the most talked about biotech topics on other popular stock trading websites. Amarin, though, in my opinion will be bought out eventually, because the market that the company targets is huge. That market is people more »

  • Reasons to Buy This Pharmaceutical Company

    By Mohsin Saeed - February 11, 2013 | Tickers: AMRN, GSK, NEPT

    The small pharmaceutical companies have a number of weaknesses when compared to big pharmaceuticals. While they usually have competent management that can effectively oversee the development of a drug candidate, it is extremely rare that they also possess the resources to effectively market their own product. This is the very reason small pharmaceuticals are such attractive acquisition plays. If a company has managed to develop an interesting candidate it is more »

  • What Exactly is Wrong With Amarin Shares

    By Chris Lau - January 24, 2013 | Tickers: AMRN, ARNA, VVUS

    Since peaking in July, 2012 at around $15, shares of Amarin (NASDAQ: AMRN) declined steadily to close recently at $8.47. Amarin was flying high last summer because investors were betting that the company would be taken over. Investors also expected that positive FDA decisions would drive Amarin shares higher. More recently, in comparison to other pharmaceutical companies rallying on FDA-related news, Amarin continued an additional decline of over 20 more »

  • Four Sell-Offs that Might Create Opportunity

    By Brian Nichols - January 22, 2013 | Tickers: AMRN, ARNA, INTC, MLNX

    Last Friday there were numerous high-profile stocks to fall lower -- some caught my attention while others did not. The ones that did catch my attention were violent falls, or aggressive selling, due to fundamental and technical fear. However, in the midst of these downtrends there could be value, and I am looking at four such situations.

    Bad News for Intel Might be Priced Into the Stock

    Intel (NASDAQ: INTC) has more »

  • Monday’s Small and Midcap Outperformers Could Indicate 2013’s Rally Stocks

    By Brian Nichols - January 2, 2013 | Tickers: DDD, ANF, AKS, AMRN, BBY

    Earlier on Tuesday I published an article that looked at several large cap stocks that could rally into 2013 as a result of fund rebalancing and strong buying pressure during the final day of 2012. This would be consistent with past trends, as investors look to buy hot stocks that finish a year strong, and then ride those same stocks into a new year. Therefore, in this article, I am more »

  • Ignore the Fiscal Cliff: 1 Bullish Idea From 4 Tech Stocks Under $6

    By Chris Lau - December 31, 2012 | Tickers: AMRN, BRCD, GRPN, MU, OCZ, SIRI

    Between Nov. 30 and Dec. 14, short-selling volumes increased for a range of companies in various sectors. In the volatile pharmaceutical and biotech sector, companies like Amarin and Dendreon  experienced a 15% increase in short-selling.  In the technology sector, bearishness increased for OCZ Technology (NASDAQ: OCZ) and Sirius XM Radio (NASDAQ: SIRI) each by 9%. Investors were also more bearish on Brocade Communications (NASDAQ: BRCD).  In this article, four technology more »

  • 5 Picks for 2013

    By Michael Mistaleski - December 31, 2012 | Tickers: AXAS, AMRN, ARNA, EOX, HEK

    Seems like everyone makes their predictions this time of year. Business publications, talking heads and fund managers spouting the next sure thing for the coming year. So what separates my picks from the rest? I own all five of my picks. I have put my money where my mouth is. Let me take you through each one.

    Let us start with Amarin (NASDAQ: AMRN). Ever since they announced on Dec more »

  • Healthcare Outlook: Sector and Company Predictions for 2013

    By Brian Nichols - December 28, 2012 | Tickers: AMRN, ARNA, SRPT, SPPI

    In an attempt to gauge the health and direction of the economy, I am breaking down each sector, one by one. In this article, I am looking at healthcare, a sector that has underperformed the market but one with components that have significantly outperformed the market.

    Healthcare outlook

    Healthcare is a unique sector, because it is the only one that is both secular and cyclical. It’s cyclical because it more »

  • Three Stocks with Q4 Losses Will Trade Higher

    By Brian Nichols - December 27, 2012 | Tickers: AMRN, AAPL, MLNX

    Stocks in the coal and solar industry have bounced off their bottom lows to trade considerably higher with other fallen stocks such as Nokia during the last six months. Now, there is a new group of fallen stocks, but with the market’s history of reversing trends in January, I believe that several of this group will trade higher in the near future. And in this article, I am looking more »

  • Is Amarin Still a Buy?

    By Mohsin Saeed - December 26, 2012 | Tickers: AMRN, AZN, GSK, PFE, TEVA

    Amarin (NASDAQ: AMRN) announced earlier this month that it planned to commercialize Vascepa. The stock tanked as investors were hoping that Amarin would find a buyer soon and therefore were considering Amarin a short-term investment. The primary hurdle in the acquisition of Amarin has been the NCE status. The FDA has still not classified if Amarin will get 5-year or 3-year exclusivity for Vascepa. This makes it very difficult for more »

  • 2 New Growth Catalysts Could Send This Stock Higher

    By Jordo Bivona - December 24, 2012 | Tickers: ACAD, AMRN, GSK, SRPT

    Sarepta Therapeutics (NASDAQ: SRPT) is focused on developing first-in-class RNA-based therapies to improve and save the lives of people affected by rare and infectious diseases. Its diverse pipeline of RNA-based therapies has given way to its lead program, eteplirsen, for Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases. After twenty two years in relative more »

  • Following A Plan Doesn't Matter Anymore

    By Spencer Knight - December 14, 2012 | Tickers: AMRN, DNDN, REGN

    There has been quite the fuss over Amarin (NASDAQ: AMRN) lately.  Investors have been hoping for the fish-oil drug maker to be bought out by a larger firm or, at the very least, receive some sort of marketing agreement for the firm’s only FDA approved drug, Vascepa.  Because of the lack of any material deal the stock has been a cliff jumper since its approval in late July.

    More more »

  • ARNA: Analysis of Risk and Reward

    By Mohsin Saeed - December 14, 2012 | Tickers: AMRN, ARNA, GILD, PFE, VVUS

    The last year has been an interesting one in the Bio Technology industry, as a number of drugs have gained FDA approval. The Food and Drug Administration has given its nod of approval to a number of drugs, including Vivus' (NASDAQ: VVUS) Qsymia, Arena Pharmaceutical's (NASDAQ: ARNA) Belviq, Gilead Science's (NASDAQ: GILD) Stribild, Pfizer's (NYSE: PFE) Xeljanz, etc. Amarin's (NASDAQ: AMRN) Vascepa also received FDA approval more »

  • Page 1 of 2